NASDAQ · Key Statistics

ARS Pharmaceuticals, Inc. (SPRY) P/E Ratio, ROE & Key Statistics

$3.65 NASDAQ: SPRY Market Cap $366.93M

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for ARS Pharmaceuticals, Inc. (SPRY), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-1.93
P/B ratioShare price divided by book value per share.-32.44
P/S ratioMarket value divided by annual revenue.3.20
PEG ratioP/E divided by the earnings growth rate.0.02
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.-2.95
EV / RevenueEnterprise value against annual revenue.4.61
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.-51.81%
Free cash flow yieldFree cash flow as a percentage of market value.-46.81%
Price / free cash flowMarket value divided by free cash flow.-2.14

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.73.45%
Operating marginRevenue left after operating costs.-161.50%
Net marginRevenue left after every cost, including tax and interest.-163.64%
Return on equityProfit as a percentage of shareholders’ equity.-453.93%
Return on assetsProfit as a percentage of total assets.-79.48%
Return on capital employedOperating profit against the capital the business uses.-105.72%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.3.25
Quick ratioThe same, excluding inventory.3.07
Cash ratioCash alone against current liabilities.1.05
Debt to equityTotal borrowings against shareholders’ equity.-16.48
Debt to assetsTotal borrowings against total assets.0.29
Interest coverageHow many times operating profit covers the interest bill.-26.40

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$1.74
Book value per shareShareholders’ equity divided by shares outstanding.−$0.12
Market capitalisationShare price times shares outstanding.$366.93M
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.$562.05M

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

ARS Pharmaceuticals, Inc. (SPRY) statistics — frequently asked questions

What is ARS Pharmaceuticals, Inc.'s P/E ratio?

ARS Pharmaceuticals, Inc. (SPRY) trades on a price-to-earnings ratio of -1.93. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is ARS Pharmaceuticals, Inc.'s return on equity?

ARS Pharmaceuticals, Inc. (SPRY) reports a return on equity of -453.93%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does ARS Pharmaceuticals, Inc. carry?

ARS Pharmaceuticals, Inc. (SPRY) has a debt-to-equity ratio of -16.48, which compares total borrowings with shareholders' equity.

What is ARS Pharmaceuticals, Inc.'s profit margin?

ARS Pharmaceuticals, Inc. (SPRY) keeps -163.64% of revenue as net profit after every cost, including tax and interest.

P/E and ROE of other Biotechnology stocks

VRTX P/E 34.56REGN P/E 19.22MRNA ROE -37.62%RVMD ROE -91.93%ROIV ROE -6.12%INSM ROE -82.75%UTHR P/E 21.31INCY P/E 55.62ALNY P/E 36.02ASND P/E 17.60All Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.